38
Participants
Start Date
August 9, 2022
Primary Completion Date
February 12, 2025
Study Completion Date
February 12, 2025
RP-6306 (oral PKMYT1 inhibitor)
RP-6306 (Oral) in combination with FOLFIRI (IV)
#1008, Columbia University, New York
#1022, Moffitt Cancer Center, Tampa
#1001, The University of Texas M.D. Anderson Cancer Center, Houston
#1013, The University of Utah, Huntsman Cancer Center, Salt Lake City
#1019, UCLA, Westwood Cancer Center, Los Angeles
# 2001, Princess Margaret Cancer Centre, Toronto
# 5002, South Texas Accelerated Research Therapeutics, Madrid
# 5003, Hospital Universitario HM Sanchinarro, Madrid
# 3003, Sarah Cannon Research Institute, London
Lead Sponsor
Repare Therapeutics
INDUSTRY